Neurocrine Biosciences, Inc.
MX ˙ BMV ˙ US64125C1099
SecurityMX:NBIX / Neurocrine Biosciences, Inc.
InstitutionFORA Capital, LLC
Latest Disclosed Ownership4,157 shares
Latest Disclosed Value $ 547,767
FORA Capital, LLC ownership in NBIX / Neurocrine Biosciences, Inc.

On May 14, 2026 - FORA Capital, LLC filed a 13F-HR form disclosing ownership of 4,157 shares of Neurocrine Biosciences, Inc. (MX:NBIX) valued at $547,767 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 14, 2025 disclosing 0 shares of Neurocrine Biosciences, Inc..

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 4,157 4,157 548 0.0401
2025-02-14 2024-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 0 -16,752 -100.00 0 -100.00
2024-11-13 2024-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 16,752 16,752 1,930 0.2270
2023-11-13 2023-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 0 -2,298 -100.00 0 -100.00
2023-08-11 2023-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 2,298 -7,367 -76.22 217 -77.91 0.0308
2023-05-12 2023-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 9,665 9,665 978 0.0980
2023-02-08 2022-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 0 -8,272 -100.00 0 0.0000
2022-11-14 2022-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 8,272 8,272 1 0.1687
2021-11-15 2021-09-30 13F NEUROCRINE BIOSCIENCES, INC. CMN COM 64125C109 0 -2,863 -100.00 0 -100.00
2021-08-16 2021-06-30 13F NEUROCRINE BIOSCIENCES, INC. CMN COM 64125C109 2,863 -258 -8.27 279 -8.22 0.0519
2021-05-17 2021-03-31 13F NEUROCRINE BIOSCIENCES, INC. CMN COM 64125C109 3,121 3,121 304 0.0998
2021-02-12 2020-12-31 13F NEUROCRINE BIOSCIENCES, INC. CMN COM 64125C109 0 -2,204 -100.00 0 -100.00
2020-11-13 2020-09-30 13F NEUROCRINE BIOSCIENCES, INC. CMN COM 64125C109 2,204 -3,341 -60.25 212 -68.64 0.1390
2020-08-14 2020-06-30 13F NEUROCRINE BIOSCIENCES, INC. CMN COM 64125C109 5,545 5,545 676 0.2314
2020-05-15 2020-03-31 13F NEUROCRINE BIOSCIENCES INC CMN COM 64125C109 0 -8,281 -100.00 0 -100.00
2020-02-14 2019-12-31 13F NEUROCRINE BIOSCIENCES INC CMN COM 64125C109 8,281 8,281 890 0.0897
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.